

CARACO PHARMACEUTICAL LABORATORIES LTD
Form 8-K
February 08, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

February 8, 2007

(Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

Michigan

0-24676

38-2505723

(State or other jurisdiction of
incorporation)

(Commission file number)

(I.R.S. employer identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure

On February 8, 2007, Caraco Pharmaceutical Laboratories, Ltd. (Caraco) will be making a presentation to certain investors at a conference. The slides to be used at such presentation are furnished in Exhibit 99.1 hereto and are incorporated herein by reference. Caraco also intends to include such slide presentation on its website (<http://www.caraco.com>).

Item 9.01. Financial Statements and Exhibits

c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
--------------------	--------------------

99.1	Copy of the slides for Caraco s presentation to certain investors at February 8, 2007 conference.
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Date: February 8, 2007

By: /s/ Daniel H. Movens

Daniel H. Movens
Chief Executive Officer

Exhibit Index

99.1 Copy of the slides for Caraco's presentation to certain investors at February 8, 2007 conference.